trending Market Intelligence /marketintelligence/en/news-insights/trending/ccLGKWNe5h55S2NU9FlTBw2 content esgSubNav
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us
In This List

Stealth BioTherapeutics stock drops 66% on failed rare disease trial


Needham & Company is Now Available in the S&P Global Market Intelligence Aftermarket Research Collection


Banking Essentials Newsletter - February Edition


Message in a (Word)Cloud

Six trends shaping the industries and sectors we cover in 2021

Stealth BioTherapeutics stock drops 66% on failed rare disease trial

Stealth BioTherapeutics Corp.'s experimental therapy elamipretide for a genetic disorder affecting the skeletal muscles failed to improve patients' walking ability and fatigue in a late-stage trial.

Newton, Mass.-based Stealth's stock dropped by 66.1% to $4.72 as of 9:55 a.m. ET on Dec. 20.

The biotechnology company will assess operational resources following these results and provide next steps in January 2020, according to a Dec. 20 press release.

Elamipretide was evaluated in a 32-week phase 3 trial called MMPOWER-3 for primary mitochondrial myopathy, a rare disease characterized by mutations in the mitochondria that affect the skeletal muscle, leading to insufficient energy in the cells. Primary mitochondrial myopathy can also cause muscle fatigue, muscle pain and muscle wasting.

While elamipretide was well-tolerated among the 218 enrolled patients, the drug candidate failed to improve how far patients could walk in a six-minute walk test and fatigue and muscle weakness symptoms.

The company is also testing elamipretide for another rare mitochondrial disorder called Barth syndrome. Stealth intends to meet with the U.S. Food and Drug Administration in early 2020 to determine next steps, as elamipretide has been shown to improve patients' condition in clinical trials for Barth syndrome.